{"groups":[{"description":"Participants with rhabdoid tumors (malignant rhabdoid tumor \\[MRT\\], rhabdoid tumors of the kidney \\[RTK\\], atypical teratoid rhabdoid tumor \\[ATRT\\], and selected tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type \\[SCCOHT\\], also known as malignant rhabdoid tumor of the ovary \\[MRTO\\]) received tazemetostat 800 milligram (mg) twice daily (BID) orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG000","title":"Rhabdoid Tumors: Cohort 1"},{"description":"Participants with relapsed or refractory synovial sarcoma with SS18-SSX rearrangement received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG001","title":"Synovial Sarcoma: Cohort 2"},{"description":"Participants with other integrase interactor 1 (INI-1)-negative tumors or any solid tumor with enhancer of zeste homologue-2 (EZH2) gain of function (GOF) mutation, including epithelioid malignant peripheral nerve sheath tumor (EMPNST), extraskeletal myxoid chondrosarcoma (EMC), myoepithelial carcinoma, other INI-1-negative malignant tumors with sponsor approval, any solid tumor with EZH2 GOF mutation including but not limited to Ewing's sarcoma and melanoma received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG002","title":"Other INI1-negative: Cohort 3"},{"description":"Participants with renal medullary carcinoma (RMC) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG003","title":"RMC: Cohort 4"},{"description":"Participants with epithelioid sarcoma (ES) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG004","title":"ES: Cohort 5"},{"description":"Participants with ES undergoing optional tumor biopsy received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG005","title":"ES Paired Biopsy: Cohort 6"},{"description":"Participants with poorly differentiated chordoma (or other chordoma with sponsor approval) received tazemetostat 800 mg BID orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG006","title":"Chordoma: Cohort 7"},{"description":"Participants with ES received tazemetostat 1600 mg once daily (QD) orally in continuous 28-day cycles until disease progression, development of an unacceptable toxicity, withdrawal of consent, or termination of the study.","id":"FG007","title":"ES 1600 mg: Cohort 8"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}],"type":"Participant enrolled in rollover study"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"26"},{"groupId":"FG002","numSubjects":"22"},{"groupId":"FG003","numSubjects":"11"},{"groupId":"FG004","numSubjects":"46"},{"groupId":"FG005","numSubjects":"52"},{"groupId":"FG006","numSubjects":"7"},{"groupId":"FG007","numSubjects":"5"}],"type":"Disease progression - radiological"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"1"}],"type":"Disease progression - clinical"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"Unacceptable toxicity (related to study treatment)"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"Adverse event (not related to study treatment)"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}],"type":"Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"2"},{"groupId":"FG007","numSubjects":"1"}],"type":"Participant refused further study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}],"type":"Investigator discretion"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"2"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"33"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"14"},{"groupId":"FG004","numSubjects":"62"},{"groupId":"FG005","numSubjects":"69"},{"groupId":"FG006","numSubjects":"18"},{"groupId":"FG007","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"33"},{"groupId":"FG002","numSubjects":"32"},{"groupId":"FG003","numSubjects":"14"},{"groupId":"FG004","numSubjects":"62"},{"groupId":"FG005","numSubjects":"69"},{"groupId":"FG006","numSubjects":"18"},{"groupId":"FG007","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were enrolled into 1 of the 8 cohorts based on tumor type. A total of 267 participants were enrolled in the study.","recruitmentDetails":"This Phase II, open-label study was conducted at 28 sites in 9 countries (Australia, Belgium, Canada, France, Germany, Italy, Taiwan, United Kingdom, and United States) from 22 December 2015 to 26 February 2024."}